|  | Cancer | Breast Cancer

Understanding HER2-Positive Breast Cancer: Biology, Treatment Evolution, and Outlook

HER2-positive breast cancer (15–20% of cases) overexpresses the HER2 receptor, driving aggressive growth—but also providing a precise therapeutic target. Outcomes have dramatically improved.

What HER2+ Means

  • HER2 (ERBB2) gene amplification → protein overexpression on cell surface
  • Tested by IHC (0–3+) and/or FISH/ISH (amplification ratio)
  • IHC 3+ or FISH+ = positive. IHC 2+ requires FISH confirmation

Treatment Evolution and Current Standards

Early Stage (Curative Intent)

  • Neoadjuvant (pre-surgery): Taxane + trastuzumab + pertuzumab (± carboplatin). pCR (pathologic complete response) = strong prognostic marker
  • Adjuvant: Complete 1 year trastuzumab (± pertuzumab if high-risk). T-DM1 if residual disease post-neoadj (KATHERINE)
  • Neratinib (extended adjuvant): For HR+/HER2+ after trastuzumab (ExteNET)

Metastatic (Chronic Management)

  • 1st line: Taxane + trastuzumab + pertuzumab (CLEOPATRA)
  • 2nd line: T-DXd (trastuzumab deruxtecan) — superior PFS/OS vs T-DM1 (DESTINY-Breast03)
  • 3rd line+: T-DM1, tucatinib + capecitabine + trastuzumab (HER2CLIMB; brain mets), novel ADCs, clinical trials

Special Considerations

  • Cardiotoxicity: Trastuzumab → reversible LVEF decline (not dose-dependent). Baseline + q3mo echo/MUGA. Hold if ↓ >10% or <50%
  • Brain mets: ~30–50% lifetime incidence. Tucatinib, T-DXd, radiation (SRS/WBRT) have activity
  • HR+/HER2+ (dual positive): Add endocrine therapy to HER2-targeted backbone

Outlook

  • Early stage: 5-year OS >90% with modern regimens
  • Metastatic: Median OS now 4–5+ years (vs. ~2 pre-HER2 drugs). Some live 10+ years
  • Cure language reserved for early stage; MBC = chronic control

Action Steps

  1. Confirm HER2 status (central lab if equivocal)
  2. Get germline testing (BRCA) — informs PARPi eligibility
  3. Discuss clinical trial at every decision point
  4. Cardio-oncology coordination if cardiac risk factors
  5. Connect with HER2+ communities (SHARE, LBBC, GRASP)

HER2+ was once the worst subtype. Now it's the most targetable. Science moves fast—stay plugged in.

Breast Cancer - Related Articles